Welcome to our dedicated page for Petmed Express news (Ticker: PETS), a resource for investors and traders seeking the latest updates and insights on Petmed Express stock.
PetMed Express, Inc. reports developments tied to its PetMeds pet pharmacy platform, its PetCareRx business, and the sale of prescription and non-prescription pet medications, preventatives, health products, and supplies. The company serves pet owners through direct-to-consumer channels and has announced distribution partnerships that extend pet pharmacy offerings across retail and digital channels.
Recurring news themes include product assortments focused on pet wellness, fiscal results and financial reporting updates, Nasdaq listing-rule communications related to periodic filings, board and audit committee changes, shareholder rights plan actions, and responses to unsolicited acquisition proposals. Coverage also reflects the company's positioning as a national pet pharmacy and pet health products retailer.
PetMed Express (NASDAQ: PETS) reported first quarter 2026 net sales of $41.0 million, down 19.9% from $51.2 million a year earlier, mainly reflecting lower prescription medication sales despite reduced consumer promotions. Gross profit was $11.3 million versus $14.4 million in the prior-year period.
Net loss narrowed to $6.1 million, or $(0.28) per diluted share, from $34.2 million, or $(1.65) per share, primarily due to the absence of prior-year impairment charges and lower G&A and advertising expenses. Adjusted EBITDA was $(3.4) million compared with $(2.7) million. Operating expenses fell sharply, including a nearly 14% decline in general and administrative costs and lower advertising spend. Cash and equivalents declined to $13.1 million from $21.4 million at March 31, 2026, with $7.7 million used in operating activities. The company highlighted completion of an enterprise-wide SAP ERP rollout and a recently announced sale-leaseback aimed at strengthening its balance sheet.
PetMed Express (Nasdaq: PETS) announced it will release financial results for the first quarter of fiscal year 2027, covering the period ended June 30, 2026, on Thursday, August 13, 2026 after market close.
The company will hold a conference call and webcast to review the results at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on the same day. U.S. participants can dial 877-407-0789, while international participants can use 201-689-8562, or access the 1Q Earnings Webcast online. A telephonic replay will be available from after 7:30 p.m. Eastern Time on August 13, 2026, through August 27, 2026, via toll-free number 844-512-2921, international number 412-317-6671, using replay passcode 13761872.
PetMed Express (Nasdaq: PETS) entered a definitive agreement for a $37 million sale-leaseback with an institutional real estate investor covering its headquarters and distribution center buildings in Delray Beach, Florida. Closing is targeted within 120 days, subject to due diligence and customary conditions, including negotiating a leaseback for its office and Florida distribution center space.
According to PetMeds, the move is part of efforts to strengthen its balance sheet, optimize its asset base, and unlock real estate value while continuing to occupy its long-time headquarters and gaining additional financial flexibility for core pharmacy initiatives.
PetMeds (Nasdaq: PETS) launched a new co-branded online pet pharmacy with Rural King, giving Rural King customers access to pet medications, prescription food, preventatives and other pet health products through a digital platform powered by PetMeds. The service is available via RuralKing.com banners, Rural King email and social channels, and a dedicated link at RuralKing.PetMeds.com.
This is PetMeds’ first large-scale white-label pharmacy program, leveraging its pharmacy infrastructure, licensed pharmacists and e-commerce capabilities to support Rural King’s retail and online customer base, with AutoShip options for recurring needs. Introductory promotions RKPAW25 and RKKING50 offer sitewide discounts, subject to terms and exclusions.
PetMed Express (Nasdaq:PETS) confirmed receipt of an unsolicited, non-binding and conditional proposal from SilverCape Investments to acquire all outstanding shares for $3.00 per share in cash. This follows a prior $4.00 per share proposal made on December 11, 2025.
The Board, advised by financial and legal advisors, will evaluate the latest proposal but has made no determination and cautions there is no assurance any transaction will occur. The Board is prepared to engage with SilverCape once it executes a customary nondisclosure agreement with a standstill and continues to consider any credible value-maximizing proposal while focusing on core operations and long-term stockholder value.
PetMeds (NASDAQ:PETS) reported fourth quarter and fiscal 2026 results for the period ended March 31, 2026.
Q4 net sales were $42.8M (down 15.6% YoY) with a net loss of $4.1M. Fiscal 2026 net sales were $179.0M (down 21.1%), with a net loss of $57.3M, driven largely by a $26.7M goodwill impairment and higher costs. Adjusted EBITDA was $(2.8)M in Q4 and $(15.4)M for the year. The company also evaluated but declined unsolicited cash acquisition proposals of $4.00–$4.25 per share and will continue as an independent public company.
PetMed Express (Nasdaq:PETS), doing business as PetMeds and parent of PetCareRx, will report Q4 and fiscal year 2026 results for the period ended March 31, 2026, on Tuesday, June 2, 2026 after market close.
A conference call and webcast follow at 4:30 PM ET.
PetMeds (Nasdaq: PETS) announced a strategic partnership with Rural King on April 22, 2026 to launch a white-label pet pharmacy across Rural King retail stores and digital channels.
PetMeds will supply pharmacy infrastructure, licensed pharmacists and e-commerce capabilities to expand access to prescription medications, preventatives and pet health products, targeting millions of Rural King customers in rural communities.
Cardone Ventures submitted an unsolicited, non-binding all-cash proposal to acquire PetMed Express (Nasdaq: PETS) for $4.25 per share, implying an equity value of approximately $89 million on December 16, 2025.
The proposal is not subject to a financing contingency and is led by Brandon Dawson, Natalie Dawson, and Grant Cardone. Cardone Ventures highlights operational experience including scaling its firm to about $225 million in revenue in five years and managing over $2 billion in assets under management; Grant Cardone is described as managing over $5 billion of assets.
The offer is non-binding and conditioned on customary due diligence, a definitive agreement, and required approvals, and there is no assurance a transaction will be completed.
PetMeds (Nasdaq: PETS) confirmed receipt on Dec 11, 2025 of an unsolicited, non-binding proposal from SilverCape Investments Limited to acquire all outstanding shares for $4.00 per share in cash. The offer is subject to due diligence and execution of a definitive agreement but is not conditioned on financing. SilverCape publicly disclosed the proposal in an amendment to its Schedule 13D filed with the SEC on Dec 11, 2025. The PetMeds board, with financial and legal advisers, will review the proposal consistent with its fiduciary duties. The company said this letter is not a formal offer capable of acceptance and stockholders need take no action at this time.